Low-level Laser Therapy as an Adjunct to Non-surgical Periodontal Treatment

Not Applicable

Completed

• Conditions: Periodontal Diseases; Periodontal Disease, AVDC Stage 4; Periodontal Inflammation; Periodontal Disease, AVDC Stage 3; Periodontal Attachment Loss
• Interventions: Procedure: low level laser therapy; Procedure: non-surgical periodontal treatment

• Registration Number: NCT05233501
• Lead Sponsor: University of Beykent

Brief Summary

The present study aimed to investigate the effects of low-level laser therapy (LLLT) as an adjunct to non-surgical periodontal treatment (NSPT) on the plasminogen-activating system in Stage 3-4, Grade C periodontitis patients.

Detailed Description

Limited data is available regarding the effects of various periodontal treatment protocols on GCF t-PA and PAI-1 levels, and the extent to which LLLT in conjunction with NSPT affects these levels in patients with Stage 3-4, Grade C periodontitis is unknown. Therefore, this study measured standard clinical outcomes and GCF t-PA and PAI-1 levels in patients with Stage 3-4 Grade, C periodontitis in order to assess the use of LLLT as an adjunct to standard NSPT.

This split-mouth study was conducted with 15 Stage 3-4, Grade C periodontitis patients and 15 healthy individuals matched for age and sex. Participants were grouped as follows: Periodontitis/NSPT (Sham); Periodontitis/NSPT+LLLT (LLLT); Periodontally Healthy (Control). LLLT was applied following NSPT and again on post-treatment Days 2 and 7. Clinical parameters were recorded at baseline (i.e. before NSPT) and on Day 30. Gingival crevicular fluid (GCF) samples were collected at baseline and during follow-up visits on Days 7, 14 and 30. GCF t-PA and PAI-1 levels were measured with ELISA.

Study Timeline

• Study Start: 2017-01-01
• Primary Completion: 2017-09-30
• Study Completion: 2018-08-30
• Status Verified: 2022-01
• Study First Submitted: 2022-01-13
• Study First Submitted QC: 2022-01-31
• Last Update Submitted: 2022-01-31
• Study First Posted: 2022-02-10
• Last Update Posted: 2022-02-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• Stage 3-4, Grade C periodontitis (at least one site with probing depth (PD) and clinical attachment level (CAL) ≥5 mm in their incisors and/or first molars and at least 6 other teeth with similar PD and CAL measurements, with alveolar bone loss confirmed by radiography; familial aggregation;
• presence of ≥16 teeth;
• no periodontal treatment in the 6 months prior to data collection;
• non-smoker

Exclusion Criteria

• systemic problems, including a medical history of cancer, rheumatoid arthritis, diabetes mellitus, or cardiovascular disease;
• compromised immune system;
• pregnancy, menopause, or lactation;
• ongoing drug therapy that might affect the clinical characteristics of periodontitis;
• use of systemic antimicrobials during the 6 weeks prior to data collection

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
non-surgical treatment+ low level laser therapy	low level laser therapy	-
non-surgical perıodontal treatment	non-surgical periodontal treatment	-
non-surgical treatment+ low level laser therapy	non-surgical periodontal treatment	-

Primary Outcome Measures

Name	Time	Method
the change in GCF tissue plasminogen activator	baseline and during follow-up visits on Days 7, 14 and 30.	Gingival crevicular fluid (GCF) samples were collected before SRP treatment and on days 7, 14 and 30 of follow- up and the change of the related mediator at those time points. The Amount of the related mediator were evaluated using enzyme- linked immunosorbent assay \[ELISA\] kit.; Total amounts (pg/30 s) of the mediator collected from each sample in a 30- second period were calculated and recorded for analysis.
the change in GCF plasminogen activator inhibitor 1	baseline and during follow-up visits on Days 7, 14 and 30.	Gingival crevicular fluid (GCF) samples were collected before SRP treatment and on days 7, 14 and 30 of follow- up and the change of the related mediator at those time points. The Amount of the related mediator were evaluated using enzyme- linked immunosorbent assay \[ELISA\] kit.; Total amounts (pg/30 s) of the mediator collected from each sample in a 30- second period were calculated and recorded for analysis.

Trial Locations

Locations (1)

Beykent University; 🇹🇷 Istanbul, Turkey